JNNP: The frequency of diabetes and other complications in chronic inflammatory demyelinative multiple neurogen disease and its effect on clinical manifestations and treatment responses.

Objective: To determine the prevalence of different cogens in chronic inflammatory demyelinative multiple neuropathy (CIDP) and its effect on outcome, treatment choice and response.
method: Using structured questionnaires, information on the merger was collected from 393 CIDP patients in the Italian CIDP database that met the criteria of the European Federation of Neurology Societies and the Peripheral Neurological Association.
results: 294 patients (75 percent) reported one or more combinations, and 192 patients (49 percent) reported treatments that reduced the frequency of glucoticoid use.
75 percent (294) of patients reported at least one complication, while 54 percent (214 patients) reported more than two complications.
incidence of diabetes (14%), MGUS (12%) and other immunologic diseases (16%) among CIDP patients was significantly higher than in the European general population.
In our population, arterial hypertension (35%), cardiovascular disease (11%), thyroid disease (11%) and solid tumors (9%) are also common, but their prevalence rates are not significantly different from those reported in the Italian population.
192 (49%) patients had one or more complications that might affect treatment options, while 77 patients (19.5%) had two or more complications.
were less corticosteroids (49 percent to 61 percent; p s 0.0199) in these patients than in patients without complications.
there was no difference between the two groups in the use of IVIg (74% vs 79%; p s 0.3407) and PEx (11% vs 9%) and p s 0.6001) in the number of un treated patients (7% vs 8%); p s 0.7044).
concluded that 75 percent of CIDP patients had at least one complication, and about half of them had at least two complications.
these figures are higher than in other studies, where complications were observed between 25 and 43 per cent.
, about half of patients suffer from one or more complications that may affect treatment choices.
although less use of steroid therapy in these patients to avoid the risk of increased side effects is common in CIDP patients.
, MGUS and other immune diseases are more common in CIDP patients than in the general population.
, however, only diabetes appears to have an effect on the severity of the disease and treatment response, and may reflect the neuropathy that coexists with diabetes in some patients.
Doneddu PE, Cocito D, Manganelli F, et al Frequency of diabetes and other comorbidities in chronicitisy demyelinating polyradiculoneuropathy and their impact on clinical presentation and therapy journal of Neurology, Neurosurgery and Psimsy Published Online First: 31 August 2020. doi: 10.1136/jnnp-2020-323615 Source: MedSci Originals !-- Content Show Ends. !-- to determine if the sign-in ends.